Coexpression of activated STAT3 and DNMT1 in malignant T-cell lymphoma cells. (A) Western blot analysis with the depicted antibodies of the nuclear protein extracts from cell lines derived from T-cell lymphomas involving skin (PB-1, 2A, 2B), HTLV-I–associated (HUT102B), and anaplastic lymphoma kinase–positive (SUDHL-1, JB6, Karpas 299) malignancies. Normal T-cell–rich PBMCs, both resting and PHA activated, and B cells (RAJI and DAUDI) served as controls. (B) Immunohistochemical analysis of the cutaneous T-cell lymphoma tissues. (left) Hematoxylin-eosin staining was used to visualize malignant T cells. (middle) Anti–phospho(p)-Y705STAT3 staining. (right) Anti-DNMT1 staining. Original magnification: larger images, 100 ×; insets, 400 ×. Depicted results that show coexpression of p-STAT3 and DNMT1 by malignant T cells are representative for all biopsy tissue samples of the 15 examined patients. (C) RT-PCR analysis of DNMT1 mRNA expression in the same diverse T-cell lymphoma cell line depicted in Figure 1A, with PBMCs serving as control.